PACAP-27 vs Glucagon
Head-to-head comparison of PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) and Glucagon (Glucagon) — benefits, dosing, side effects, research data, and where to buy.
| Property | PACAP-27 | Glucagon |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Pituitary Adenylate Cyclase-Activating Polypeptide-27 | Glucagon |
| Molecular Weight | 3158 Da | 3482.75 |
| Half-Life | minutes | 5-10 min |
| Amino Acids | 27 | 29 |
| Typical Dose | Research-only: 0.1-1 nmol/kg | 1 mg IM/SC for severe hypoglycemia or 3 mg intranasal |
| Route | Intraperitoneal/Subcutaneous | IM|SC|IN|IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 220 | 93 |
| Research Status | Pre-clinical | Approved |
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Glucagon Benefits
- ✓rapid hypoglycemia reversal
- ✓raises plasma glucose
- ✓useful in emergency rescue
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Glucagon Dosing
1 mg IM/SC|3 mg intranasal
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Glucagon Side Effects
- ⚠nausea
- ⚠vomiting
Research Overview
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Glucagon
Clinical and emergency medicine use is well established for severe hypoglycemia, with newer stable formulations improving ease of administration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.